141 related articles for article (PubMed ID: 10215761)
1. Ocular toxicity and hydroxychloroquine: guidelines for screening.
Jones SK
Br J Dermatol; 1999 Jan; 140(1):3-7. PubMed ID: 10215761
[TBL] [Abstract][Full Text] [Related]
2. Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate?
Schwartzman S; Samson CM
Rheum Dis Clin North Am; 2019 Aug; 45(3):359-367. PubMed ID: 31277749
[TBL] [Abstract][Full Text] [Related]
3. Are evidence-based guidelines being followed for the monitoring of ocular toxicity of hydroxychloroquine? A nationwide survey of practice amongst consultant rheumatologists and implications for clinical governance.
Samanta A; Goh L; Bawendi A
Rheumatology (Oxford); 2004 Mar; 43(3):346-8. PubMed ID: 14963202
[TBL] [Abstract][Full Text] [Related]
4. [Eye toxicity of antimalarial agents].
Graña Gil J; Cabana Vázquez M; Vázquez González A; Sánchez Meizoso MO
An Med Interna; 2002 Apr; 19(4):189-91. PubMed ID: 12090061
[TBL] [Abstract][Full Text] [Related]
5. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.
Osadchy A; Ratnapalan T; Koren G
J Rheumatol; 2011 Dec; 38(12):2504-8. PubMed ID: 22002012
[TBL] [Abstract][Full Text] [Related]
6. What is new in recommendations on ophthalmological screening in patients treated with chloroquine and hydroxychloroquine? Update and literature review.
Wiacek MP; Bobrowska-Snarska D; Lubiński W; Brzosko M; Modrzejewska M
Niger J Clin Pract; 2017 Aug; 20(8):919-923. PubMed ID: 28891533
[TBL] [Abstract][Full Text] [Related]
7. [Update on recommendations for screening for hydroxychloroquine retinopathy].
Couturier A; Giocanti-Aurégan A; Dupas B; Girmens JF; Le Mer Y; Massamba N; Barreau E; Audo I;
J Fr Ophtalmol; 2017 Nov; 40(9):793-800. PubMed ID: 29054477
[TBL] [Abstract][Full Text] [Related]
8. Ocular toxicity of hydroxychloroquine.
Yam JC; Kwok AK
Hong Kong Med J; 2006 Aug; 12(4):294-304. PubMed ID: 16912357
[TBL] [Abstract][Full Text] [Related]
9. Hydroxychloroquine: A Brief Review on Screening, Toxicity, and Progression.
Modi YS; Singh RP; Fine HF
Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):207-17. PubMed ID: 26985794
[No Abstract] [Full Text] [Related]
10. Ocular toxicity of antimalarials in dermatology: a survey of current practice.
Cox NH; Paterson WD
Br J Dermatol; 1994 Dec; 131(6):878-82. PubMed ID: 7857843
[TBL] [Abstract][Full Text] [Related]
11. Implementation of recommendations for the screening of hydroxychloroquine retinopathy: poor adherence of rheumatologists and ophthalmologists.
Shulman S; Wollman J; Brikman S; Padova H; Elkayam O; Paran D
Lupus; 2017 Mar; 26(3):277-281. PubMed ID: 27440459
[TBL] [Abstract][Full Text] [Related]
12. [Retinal damage by (hydroxy)chloroquine intake: published evidence for an efficient ophthalmological follow-up].
Pluta JP; Rüther K
Klin Monbl Augenheilkd; 2009 Nov; 226(11):891-6. PubMed ID: 19916149
[TBL] [Abstract][Full Text] [Related]
13. [Supervision of the eyes during prolonged treatment with synthetic antimalarial drugs. Results in 237 patients followed up for 4 years on the average].
Bertrand JJ; Debeyre N; Kahn MF; Ryckewaert A
Presse Med (1893); 1968 Nov; 76(45):2139-42. PubMed ID: 5720115
[No Abstract] [Full Text] [Related]
14. Ocular toxicity of antimalarial drugs. Long-term follow-up.
Carr RE; Henkind P; Rothfield N; Siegel IM
Am J Ophthalmol; 1968 Oct; 66(4):738-44. PubMed ID: 5729592
[No Abstract] [Full Text] [Related]
15. [Ophthalmological monitoring protocol for patients treated with long-term antimalarials or vigabatrin].
Ingster-Moati I; Orssaud C
J Fr Ophtalmol; 2009 Jan; 32(1):83-8. PubMed ID: 19515321
[TBL] [Abstract][Full Text] [Related]
16. Progression of hydroxychloroquine retinopathy after discontinuation of therapy: case report.
Wei LC; Chen SN; Ho CL; Kuo YH; Ho JD
Chang Gung Med J; 2001 May; 24(5):329-34. PubMed ID: 11480331
[TBL] [Abstract][Full Text] [Related]
17. Are evidence-based guidelines being followed for the monitoring of ocular toxicity of hydroxychloroquine? A nationwide survey of practice amongst consultant rheumatologists and implications for clinical governance. Comment on the article by Samanta et al.
Mavrikakis I; Mavrikakis E
Rheumatology (Oxford); 2004 Aug; 43(8):1057-8; author reply 1059. PubMed ID: 15258296
[No Abstract] [Full Text] [Related]
18. Retinopathy and antimalarial drugs--the British experience.
Spalton DJ
Lupus; 1996 Jun; 5 Suppl 1():S70-2. PubMed ID: 8803916
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine retinal toxicity in two patients with dermatological conditions.
Kowalski T; Baker C; Mack HG
Australas J Dermatol; 2018 Nov; 59(4):e266-e268. PubMed ID: 29722012
[TBL] [Abstract][Full Text] [Related]
20. [Retinal pigment epithelium--the point about safety of antimalarial agents].
Vanheesbeke A
Bull Soc Belge Ophtalmol; 2007; (304):47-58. PubMed ID: 17718227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
